Advanced Search

Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2003 September;45(3) > Panminerva Medica 2003 September;45(3):165-73



A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Frequency: Quarterly

ISSN 0031-0808

Online ISSN 1827-1898


Panminerva Medica 2003 September;45(3):165-73


Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy

Pai S. B. 1, Pai R. B. 1,2, Schinazi R. F. 1,2

1 Veterans Affairs Medical Center, Emory University School of Medicine, Decatur, GA, USA
2 Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Decatur, GA, USA

The world­wide prob­lem of hep­a­titis B viral infec­tion has been the focus of a large num­ber of inves­ti­ga­tions. In the last ­decade advanc­es have been made in the under­stand­ing of the viral func­tion as well as strat­e­gies to com­bat the virus. Lamivudine, Hepsera, and inter­fer­on-α ther­a­pies that are cur­rent­ly used in the clin­ic are not opti­mal ­because of the emer­gence of resis­tance in the for­mer modal­ity and/or ­adverse ­effects. There are sev­er­al new nucle­osides that are under devel­op­ment for treat­ment of HBV. With the com­bi­na­tion of a num­ber of treat­ment pro­to­cols, it ­should be pos­sible to bring down the viral load to unde­tect­able lev­els and min­i­mize the risk of gen­er­at­ing muta­tions that con­fer resis­tance to the ther­a­peu­tic agent.

language: English

Full text temporarily not available online. Contact us  REPRINTS

top of page